Inventor · disambiguated record
Catherine J. Wu
Also filed as: WU CATHERINE · WU CATHERINE J · WU CATHERINE JU-YING
10 granted patents·25 pending applications·169 citations·filing 2006–2025
90Inventor score
Files withBROAD INST INC17DANA FARBER CANCER INST INC11MASSACHUSETTS GEN HOSPITAL4HACOHEN NIR1LEE PATRICK C1
Top patents by PatentIndex Score
35 records- 0196US10426824B1Compositions and methods of identifying tumor specific neoantigensMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Oct 1, 2019·19 cites·20 claims
- 0296US9115402B2Compositions and methods of identifying tumor specific neoantigensHACOHEN NIR·Filed 2011·Granted Aug 25, 2015·77 cites·46 claims
- 0395US10835585B2Shared neoantigensBROAD INST INC·Filed 2016·Granted Nov 17, 2020·26 cites·35 claims
- 0491US11834718B2Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation statusBROAD INST INC·Filed 2020·Granted Dec 5, 2023·3 cites·10 claims
- 0591US11452768B2Combination therapy with neoantigen vaccineBROAD INST INC·Filed 2014·Granted Sep 27, 2022·7 cites·32 claims
- 0691US10801070B2Compositions and methods for diagnosing, evaluating and treating cancerBROAD INST INC·Filed 2014·Granted Oct 13, 2020·26 cites·29 claims
- 0790US10993997B2Methods for profiling the t cell repertoireBROAD INST INC·Filed 2015·Granted May 4, 2021·7 cites·41 claims
- 0882US11725237B2Polymorphic gene typing and somatic change detection using sequencing dataBROAD INST INC·Filed 2014·Granted Aug 15, 2023·3 cites·4 claims
- 0977US12394502B2Method for predicting HLA-binding peptides using protein structural featuresMASSACHUSETTS GEN HOSPITAL·Filed 2020·Granted Aug 19, 2025·1 cites·19 claims
- 1070US2023190896A1Combination therapy with neoantigen vaccineBROAD INST INC·Filed 2022·Application pending·0 cites
- 1169US2020069783A1Compositions and methods of identifying tumor specific neoantigensMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 1269US2020016251A1Compositions and Methods of Identifying Tumor Specific NeoantigensDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1368US2025290139A1Diagnosis and prognosis of richter's syndromeBROAD INST INC·Filed 2024·Application pending·0 cites
- 1468US2019060432A1Compositions and methods of identifying tumor specific neoantigensMASSACHUSETTS GEN HOSPITAL·Filed 2018·Application pending·0 cites
- 1566US12435372B2Methods for profiling the T-cell-receptor repertoireBROAD INST INC·Filed 2021·Granted Oct 7, 2025·0 cites·24 claims
- 1666US2021220455A1Compositions and methods for personalized neoplasia vaccinesBROAD INST INC·Filed 2020·Application pending·0 cites
- 1765US2018055922A1Compositions and methods of identifying tumor specific neoantigensDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 1864US2024091259A1Generation of anti-tumor t cellsDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1962US2020368337A1Shared neoantigensBROAD INST INC·Filed 2020·Application pending·0 cites
- 2061US2016331822A1Compositions and methods of identifying tumor specific neoantigensDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites
- 2158US2016008447A1Compositions and methods of identifying tumor specific neoantigensDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2256US2023287510A1Compositions, panels, and methods for characterizing chronic lymphocytic leukemiaWU CATHERINE J·Filed 2021·Application pending·0 cites
- 2354US2022298580A1Immune signatures predictive of response to pd-1 blockade in richter's transformationDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2453US2022401460A1Modulating resistance to bcl-2 inhibitorsDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 2552US2016101170A1Compositions and methods for personalized neoplasia vaccinesBROAD INST INC·Filed 2015·Application pending·0 cites
- 2650US2025255889A1Methods for treatment selection for chronic lymphocytic leukemia (cll)BROAD INST INC·Filed 2025·Application pending·0 cites
- 2749US2023203485A1Methods for modulating mhc-i expression and immunotherapy uses thereofLEE PATRICK C·Filed 2021·Application pending·0 cites
- 2847US2022062394A1Methods for identifying neoantigensBROAD INST INC·Filed 2019·Application pending·0 cites
- 2946US2006292599A1Methods to detect lineage-specific cellsDANA FARBER CANCER INST INC·Filed 2006·Application pending·0 cites
- 3046US2023248814A1Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopesBROAD INST INC·Filed 2021·Application pending·0 cites
- 3142US2021382068A1Hla single allele linesDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 3241US2014364439A1Markers associated with chronic lymphocytic leukemia prognosis and progressionBROAD INST INC·Filed 2012·Application pending·0 cites
- 3338US2019300967A1Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signatureDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 3436US2019346442A1Improved hla epitope predictionBROAD INST INC·Filed 2017·Application pending·0 cites
- 3534US2017298441A1Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patientsDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Catherine J. Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →